Privileged Access Management

IDEXX Laboratories (NASDAQ: IDXX) executive Nimrata Hunt plans exit with package. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. IDEXX Laboratories announced that Executive Vice President, Global Strategy and Commercial, Nimrata Hunt, PhD, will leave her role effective April 13, 2026, then serve as a special advisor on an as-needed basis until July 13, 2026. Under a separation agreement, IDEXX will provide salary continuation for 104 weeks totaling $1,230,000 and pay her target annual bonus for two years totaling $984,000, alongside a $50,000 COBRA-related lump sum, $10,000 in transition assistance and up to $6,000 per year for 2025 and 2026 tax or financial planning services. Unvested stock options, restricted stock units and performance stock units will be forfeited as of the final employment date, while vested stock options remain exercisable under existing award terms. IDEXX characterizes the move as a termination without cause tied to elimination of her position and obtained a broad release, non-disparagement and ongoing cooperation commitments. Insights. Mid-level leadership change with structured severance, limited direct financial impact. The departure of IDEXX's Executive Vice President, Global Strategy and Commercial, is framed as a termination without cause due to position elimination. While senior, this is not a C-suite role, and the filing emphasizes an orderly transition with an advisory period through July 13, 2026. Cash obligations include salary continuation of $1,230,000, target bonuses totaling $984,000, and smaller benefits like COBRA support and transition assistance. Unvested equity is forfeited, which limits ongoing dilution. Overall, this appears to be a standard executive separation package rather than a transformational event. 8-K event classification. 2 items: 5.02, 9.01 03/26/2026 - 08:30 AM On March 24, 2026, IDEXX Laboratories, Inc. ("IDEXX") and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the "Separation Date") and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the "Final Employment Date"). IDEXX and Dr. Hunt entered into a separation letter agreement (the "Separation Agreement") to memorialize the terms of Dr. Hunt's advisory role and subsequent departure. Pursuant to the Separation Agreement, IDEXX will pay to Dr. Hunt separation benefits in the form of (i) salary continuation for 104 weeks following the Separation Date, in the aggregate amount of $1,230,000; (ii) Dr. Hunt's target annual bonus for two years, in the aggregate amount of $984,000, payable together with the salary continuation payments, (iii) a lump-sum payment of $50,000, representing 78 weeks of COBRA premium costs with respect to Dr. Hunt's continued coverage under the IDEXX medical, dental and/or vision plans; (iv) transition assistance benefit of $10,000; and (v) reimbursement of tax preparation or financial planning services for the 2025 and 2026 tax years in an amount not to exceed $6,000 per tax year (to the extent not reimbursed prior to the Separation Date). Vesting of stock option, restricted stock unit and performance stock unit awards previously issued to Dr. Hunt under IDEXX's stock incentive plans will cease effective as of the Final Employment Date, and all unvested awards will be forfeited. Dr. Hunt's stock option awards, to the extent vested and exercisable, will remain exercisable during the period following the Final Employment Date that is specified in the applicable award agreements. Dr. Hunt's position with IDEXX is being eliminated, and, as a result, IDEXX deems Dr. Hunt's separation to be a termination of employment without cause for purposes of determining Dr. Hunt's separation benefits. The Separation Agreement also contains a general release of claims in favor of IDEXX (including a reaffirmation thereof on or following the Separation Date and on or following the Final Employment Date), non-disparagement and continuing cooperation covenants and an acknowledgement by Dr. Hunt that she continues to be bound by restrictive covenants applicable to her under the Confidential Information, Work Product, and Restrictive Covenant Agreement between her and IDEXX dated January 24, 2022. All of the foregoing serves as consideration for IDEXX's payment of separation benefits described in the Separation Agreement. Following the Separation Date, IDEXX will compensate Dr. Hunt for her services as a special advisor until the Final Employment Date with respect to days worked at IDEXX's request, with a per diem payment calculated based on her current base salary rate. A copy of the Separation Agreement is included as Exhibit 10.1 to this Current Report on Form 8-K. The description of the Separation Agreement included in this Current Report on Form 8-K is a summary, is not complete and is qualified in its entirety by reference to the terms of the Separation Agreement filed as Exhibit 10.1 hereto. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What executive change did IDEXX (IDXX) disclose for Nimrata Hunt? IDEXX disclosed that Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, will leave her role on April 13, 2026 and then serve as a special advisor until July 13, 2026, under a negotiated separation and advisory arrangement. What cash severance will Nimrata Hunt receive from IDEXX (IDXX)? Nimrata Hunt will receive salary continuation for 104 weeks totaling $1,230,000 and target annual bonus payments for two years totaling $984,000, plus a $50,000 COBRA-related lump sum, $10,000 in transition assistance and up to $6,000 per year for tax or financial planning services. How does the IDEXX (IDXX) separation agreement treat Nimrata Hunt's equity awards? All unvested stock option, restricted stock unit and performance stock unit awards will be forfeited as of the final employment date. Vested and exercisable stock options will remain exercisable for the periods specified in the existing award agreements, preserving only her already vested equity rights. Why does IDEXX (IDXX) classify Nimrata Hunt's departure as without cause? IDEXX states that Nimrata Hunt's position is being eliminated, and therefore views her separation as a termination of employment without cause for determining severance. This classification underpins her eligibility for the salary continuation, bonus payments and other separation benefits outlined in the agreement. What non-cash obligations did IDEXX (IDXX) include in Nimrata Hunt's separation terms? The separation terms require Nimrata Hunt to provide a general release of claims, reaffirmed at specific dates, and include non-disparagement and cooperation covenants. She also acknowledges ongoing restrictive covenants from a prior confidentiality and restrictive covenant agreement, supporting IDEXX's protection of information and business relationships. How will IDEXX (IDXX) pay Nimrata Hunt for advisory services after her role ends? After her executive role ends on April 13, 2026, IDEXX will compensate Nimrata Hunt as a special advisor through July 13, 2026. She will receive per diem payments for days worked at IDEXX's request, calculated using her current base salary rate under the separation agreement. Filing exhibits & attachments. 4 documents Agreements & contracts.

IDEXX Laboratories has raised concerns for investors despite strong performance in its Companion Animal Group business. The Zacks Rank #3 stock has rallied 43.9% over the past year, outperforming both its industry and the S&P 500, with a market capitalisation of $51.7 billion. The company's CAG Diagnostics recurring revenues increased 10% organically in the fourth quarter of 2025, driven by new innovations including the Cancer Dx diagnostic panel and inVue Dx cellular analyser. Veterinary software and diagnostic imaging revenues grew 13% organically. IDEXX is expanding internationally, planning to enter three new countries by 2026 and introducing the Cancer Dx panel to international markets in the first quarter. However, weak solvency and macroeconomic pressures present challenges for the company's operations.

IDEXX Laboratories has raised investor attention following recent share price volatility, with the stock closing at $656.73. The company showed a 3.3% seven-day return but a 9.9% decline over three months, whilst one-year total shareholder return reached 50.2%. Trading at $656.73 against a fair value estimate of $750.23, IDEXX appears 12.5% undervalued according to analyst narratives. The company's adoption of diagnostic platforms like inVue Dx and Cancer Dx is expanding its addressable market and driving recurring revenue growth, with annual revenue growing 8.3% and net income rising 9.8%. However, IDEXX's price-to-earnings ratio of 49.4x significantly exceeds the US Medical Equipment industry average of 30.9x, raising questions about whether the premium valuation reflects quality or represents valuation risk.